《大行報告》麥格理上調新秀麗(01910.HK)目標價至27元 評級「跑贏大市」
新秀麗(01910.HK)去年純利1,430萬美元,相比上一年度虧損12.78億美元,虧轉盈。麥格理髮表報告,指儘管新秀麗可能會因俄烏戰事和中國封城帶來的一些短期不利因素,但由於旅行需求,復甦趨勢應該會繼續。該行重申新秀麗「跑贏大市」評級,目標價由26元上調至27元。
新秀麗管理層預計,2022年第一季營業額與2019年相比將下降25%-27%,並維持全年15%-20%的下降指引,意味着按季改善,並有信心毛利率達55%。
麥格理將新秀麗2022年和2023年淨利潤預測分別上調18.8%和33.3%,以考慮強勁的經營槓桿和毛利率恢復。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.